COPD heterogeneity: What this will mean in practice

Respiratory Care

Volumn 56, Issue 8, 2011, Pages 1181-1187

  Rennard, Stephen I ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Chronic obstructive pulmonary disease; COPD

Indexed keywords

ROFLUMILAST;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CLINICAL PRACTICE; COMORBIDITY; COMPARATIVE EFFECTIVENESS; COST CONTROL; COST OF ILLNESS; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; EMPHYSEMA; FORCED EXPIRATORY VOLUME; GENETIC RISK; HEALTH CARE COST; HEALTH CARE PLANNING; HUMAN; LUNG RESECTION; LUNG VENTILATION PERFUSION RATIO; NATIONAL HEALTH ORGANIZATION; NUTRITIONAL STATUS; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; PROCESS DEVELOPMENT; PROGNOSIS; RESPIRATORY AIRFLOW; RISK FACTOR; SMOKING HABIT; SOCIAL STATUS;

GENETIC HETEROGENEITY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; RESPIRATORY THERAPY; SMOKING;

EID: 80051478532     PISSN: 00201324     EISSN: 19433654     Source Type: Journal    
DOI: 10.4187/respcare.01419     Document Type: Article

References (56)

1. Shapiro SD, Reilly JJ Jr, Rennard SI. Chronic bronchitis and emphysema. In: Mason RJ, Broaddus VC, Martin TR, King TE Jr, Schraufnagel DE, Murray JF, and Nadel JA, editors. Textbook of respiratory medicine, 5th edition, volume I. Saunders Philadelphia: Saunders Elsevier; 2010:919-967
2. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006;367(9524):1747-1757.
3. Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in nonsmokers. Lancet 2009;374(9691):733-743.
4. Tashkin DP, Clark VA, Coulson AH, Simmons M, Bourque LB, Reems C, et al. The UCLA population studies of chronic obstructive respiratory disease. VIII. Effects of smoking cessation on lung function: a prospective study of a free-living population. Am Rev Respir Dis 1984;130(5):707-715.
5. Ulrik CS, Backer V. Nonreversible airflow obstruction in life-long nonsmokers with moderate to severe asthma. Eur Respir J 1999; 14(4):892-896.
6. Lange P, Parner J, Vestbo J, Schnohr P, Jensen G. A 15-year follow- up study of ventilatory function in adults with asthma. N Engl J Med 1998;339(17):1194-1200.
7. Barker DJ, Godfrey KM, Fall C, Osmond C, Winter PD, Shaheen SO. Relation of birthweight and childhood respiratory infection to adult lung function and death from chronic obstructive airways disease. BMJ 1991;303(6804):671-675.
8. Shaheen SO, Sterne JA, Florey CD. Birth weight, childhood lower respiratory tract infection, and adult lung function. Thorax 1998; 53(7):549-553.
9. Weiss ST, Ware JH. Overview of issues in the longitudinal analysis of respiratory data. Am J Respir Crit Care Med 1996;154(6 Pt 2): S208-S211.
10. Tager I, Segal M, Speizer F, Weiss S. The natural history of forced expiratory volumes. Effect of cigarette smoking and respiratory symptoms. Am Rev Respir Dis 1988;138(4):837-849.
11. Brostrom EB, Thunqvist P, Adenfelt G, Borling E, Katz-Salamon M. Obstructive lung disease in children with mild to severe BPD. Respir Med 2010;104(3):362-370.
12. M, Carraro S, Baraldi E. From BPD to COPD? The hypothesis is intriguing but we lack lung pathology data in humans. Eur Respir J 2010;35(6):1419-1420; author reply 1420.
13. Shaheen SO, Barker DJ, Shiell AW, Crocker FJ, Wield GA, Holgate ST. The relationship between pneumonia in early childhood and impaired lung function in late adult life. Am J Respir Crit Care Med 1994;149(3 Pt 1):616-619.
14. United States Surgeon General. The health consequences of smoking: chronic obstructive lung disease. US Dept. of Health and Human Resources;1984;84-50205.
15. Higgins MW, Thom T. Incidence, prevalence, and mortality: intraand intercountry differences. In: Hensley MJ, Saunders NA, editors. Clinical epidemiology of chronic obstructive pulmonary disease. New York: Marcel Dekker; 1990:23-43.
16. Sherrill D, Lebowitz M, Burrows B. Epidemiology of chronic obstructive pulmonary disease. Clin Chest Med 1990;11(3):375-387.
17. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007;370(9589):765-773.
18. Matthews KA, Gallo LC. Psychological perspectives on pathways linking socioeconomic status and physical health. Annu Rev Psychol 2011;62:501-530.
19. Shavers VL. Measurement of socioeconomic status in health disparities research. J Natl Med Assoc 2007;99(9):1013-1023.
20. Sahebjami H, Vassallo CL. Effects of starvation and refeeding on lung mechanics and morphometry. Am Rev Respir Dis 1979;119(3): 443-451.
21. Karlinsky JB, Goldstein RH, Ojserkis B, Snider GL. Lung mechanics and connective tissue levels in starvation-induced emphysema in hamsters. Am J Physiol 1986;251(2 Pt 2):R282-R288.
22. Coxson HO, Chan IH, Mayo JR, Hlynsky J, Nakano Y, Birmingham CL. Early emphysema in patients with anorexia nervosa. Am J Respir Crit Care Med 2004;170(7):748-752.
23. J, Fenigstein H. Anatomie pathologique de la maladie de famine. In: Apfelbaum E, editor. Maladie de famine. Warsaw, Poland: American Joint Distribution Committee; 1946:21-27. French.
24. Black PN, Scragg R. Relationship between serum 25-hydroxyvitamin d and pulmonary function in the third national health and nutrition examination survey. Chest 2005;128(6):3792-3798.
25. Silverman EK. Progress in chronic obstructive pulmonary disease genetics. Proc Am Thorac Soc 2006;3(5):405-408.
26. Silverman EK, Spira A, Paré PD. Genetics and genomics of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2009;6(6):539-542.
27. Hersh CP, Demeo DL, Lazarus R, Celedon JC, Raby BA, Benditt JO, et al. Genetic association analysis of functional impairment in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;173(9):977-984.
28. Larsson C. Natural history and life expectancy in severe alpha 1-antitrypsin deficiency, Pi Z. Acta Med Scand 1978;204(5):345-351.
29. Niewoehner, D. Structure-function relationships: the pathophysiology of airflow obstruction. In: Stockley R, Rennard S, Rabe K, Celli B, editors. Chronic obstructive pulmonary disease. Malden, MA: Wiley-Blackwell; 2007:3-19.
30. Hogg JC, Timens W. The pathology of chronic obstructive pulmonary disease. Annu Rev Pathol 2009;4:435-459.
31. J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen city Heart Study Group. Am J Respir Crit Care Med 1996;153(5):1530-1535.
32. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004;350(26):2645-2653.
33. Hogg JC, Macklem PT, Thurlbeck WM. Site and nature of airway obstruction in chronic obstructive lung disease. N Engl J Med 1968; 278(25):1355-1360.
34. Matsuba K, Thurlbeck WM. The number and dimensions of small airways in nonemphysematous lungs. Am Rev Respir Dis 1971; 104(4):516-524.
35. Matsuba K, Wright JL, Wiggs BR, Pare PD, Hogg JC. The changes in airways structure associated with reduced forced expiratory volume in one second. Eur Respir J 1989;2(9):834-839.
36. Saetta M. Destructive index: a measurement of lung parenchymal destruction in smokers. Am Rev Respir Dis 1985;131(5):764-769.
37. Calverley PM, Burge PS, Spencer S, Anderson JA, Jones PW. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 2003;58(8):659-664.
38. O'Donnell DE. Dyspnea in advanced chronic obstructive pulmonary disease. J Heart Lung Transplant 1998;17(6):544-554.
39. O'Donnell DE, Banzett RB, Carrieri-Kohlman V, Casaburi R, Davenport PW, Gandevia SC, et al. Pathophysiology of dyspnea in chronic obstructive pulmonary disease: a roundtable. Proc Am Thorac Soc 2007;4(2):145-168.
40. Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363(12):1128-1138.
41. Rennard SI, Calverley PM, Goehring UM, Bredenbröker D, Martinez FJ. Reduction of exacerbations by the PDE4 inhibitor roflumilast: the importance of defining different subsets of patients with COPD. Respir Res 2011;12:18.
42. Fabbri LM, Luppi F, Beghe B, Rabe KF. Complex chronic comorbidities of COPD. Eur Respir J 2008;31(1):204-212.
43. Burgel PR, Paillasseur JL, Caillaud D, Tillie-Leblond I, Chanez P, Escamilla R, et al. Clinical COPD phenotypes: a novel approach using principal component and cluster analyses. Eur Respir J 2010; 36(3):531-539.
44. Paoletti M, Camiciottoli G, Meoni E, Bigazzi F, Cestelli L, Pistolesi M, Marchesi C. Explorative data analysis techniques and unsupervised clustering methods to support clinical assessment of chronic obstructive pulmonary disease (COPD) phenotypes. J Biomed Inform 2009;42(6):1013-1021.
45. Celli BR, Calverley PM, Rennard SI, Wouters EF, Agusti A, Anthonisen N, et al. Proposal for a multidimensional staging system for chronic obstructive pulmonary disease. Respir Med 2005;99(12): 1546-1554.
46. Wegner RE, Jorres RA, Kirsten DK, Magnussen H. Factor analysis of exercise capacity, dyspnoea ratings and lung function in patients with severe COPD. Eur Respir J 1994;7(4):725-729.
47. Carlson, DJ, Ries AL, Kaplan RM. Prediction of maximum exercise tolerance in patients with COPD. Chest 1991;100(2):307-311.
48. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004;350(10):1005-1012.
49. Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010; 181(4):315-323.
50. Cho MH, Washko GR, Hoffmann TJ, Criner GJ, Hoffman EA, Martinez FJ, et al. Cluster analysis in severe emphysema subjects using phenotype and genotype data: an exploratory investigation. Respir Res 2010;11:30.
51. Fishman A, Martinez F, Naunheim K, Piantadosi S, Wise R, Ries A, et al. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003; 348(21):2059-2073.
52. Gross NJ, Giembycz MA, Rennard SI. Treatment of chronic obstructive pulmonary disease with roflumilast, a new phosphodiesterase 4 inhibitor. COPD 2010;7(2):141-153.
53. Rabe KF, Bateman ED, O'Donnell D, Witte S, Bredenbroker D, Bethke TD. Roflumilast: an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005;366(9485):563-571.
54. Calverley PM, Sanchez-Toril F, McIvor A, Teichmann P, Bredenbroeker D, Fabbri LM. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;176(2):154-161.
55. PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ; M2-124 and M2-125 Study Groups. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009;374(9691):685-694.
56. Erratum in: Lancet 2010;376(9747):1146.